LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus.
Anna C Nilsson, Håkan Janson, Hedda Wold, Anders Fugelli, Karin Andersson, Camilla Håkangård, Pernilla Olsson, Wenche Marie Olsen
Index: Antimicrob. Agents Chemother. 59(1) , 145-51, (2014)
Full Text: HTML
Abstract
Nasal decolonization has a proven effect on the prevention of severe Staphylococcus aureus infections and the control of methicillin-resistant S. aureus (MRSA). However, rising rates of resistance to antibiotics highlight the need for new substances for nasal decolonization. LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. This mechanism of action is not associated with cross-resistance and has a low propensity for development of resistance. In the present study, persistent nasal MRSA and methicillin-sensitive S. aureus (MSSA) carriers were treated for 3 days with vehicle or with 1%, 2%, or 5% LTX-109. A significant effect on nasal decolonization was observed already after 2 days of LTX-109 treatment in subjects treated with 2% or 5% LTX-109 compared to vehicle (P ≤ 0.0012 by Dunnett's test). No safety issues were noted during the 9-week follow-up period. Minimal reversible epithelial lesions were observed in the nasal cavity. The systemic exposure was very low, with a maximum concentration of drug in plasma (Cmax) at 1 to 2 h postdosing (3.72 to 11.7 ng/ml). One week after treatment initiation, LTX-109 was not detectable in any subject. Intranasal treatment of S. aureus with LTX-109 is safe and reduces the bacterial load already after a single day of treatment. Hence, LTX-109 has potential as a new and effective antimicrobial agent with a low propensity of resistance development that can prevent infections by MSSA/MRSA during hospitalization. (This study has been registered at ClinicalTrials.gov under registration no. NCT01158235.). Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Related Compounds
Related Articles:
2014-08-01
[Mol. Plant 7(8) , 1365-83, (2014)]
Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium.
2014-12-11
[Oncogene 33(50) , 5688-96, (2014)]
Functional consequence of the MET-T1010I polymorphism in breast cancer.
2015-02-20
[Oncotarget 6(5) , 2604-14, (2015)]
Aptamer-based polyvalent ligands for regulated cell attachment on the hydrogel surface.
2015-04-13
[Biomacromolecules 16(4) , 1382-9, (2015)]
2015-04-01
[J. Pineal Res. 58(3) , 310-20, (2015)]